Medscape is available in 5 Language Editions – Choose your Edition here.


Endocrine Myopathies Clinical Presentation

  • Author: Wayne E Anderson, DO, FAHS, FAAN; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
Updated: Aug 25, 2014


Usually, multiple organ systems are involved and myopathy is only one part of the history, although exceptions do occur and are noted in Pathophysiology.

The history of myopathy in general is that of proximal more than distal muscle weakness, with or without associated muscle pain, cramps, and/or spasms. The weakness is typically symmetric or rapidly becomes symmetric. Muscle atrophy may or may not be present.

  • Adrenal dysfunction
    • Hypoadrenalism: In hypoadrenalism, the neurological manifestations of behavioral disturbance and mentation are prominent; myopathy is not a frequent presenting finding.
    • Hyperadrenalism: Cushing syndrome may present with the usual cushingoid features plus pain and weakness. Corticosteroid myopathy is the most common endocrine-related muscle disease. Please refer to the article Cushing Syndrome for details.
  • Thyroid dysfunction: Disorders of thyroid function may result in muscle weakness, and determination of thyroid function remains an integral part of the evaluation for muscle weakness.
    • Hypothyroidism: Muscle weakness occurs most prominently in the adult forms of myxedema. General symptoms include weight gain, neuropathy, fatigue, cold intolerance, sleepiness, and emotional disturbances in addition to muscle stiffness, weakness, and pain. Notably, psychiatric disease may be prominent. Cerebellar ataxia may be seen in adults, less often in children, in whom cerebellar involvement is more midline.
    • Hyperthyroidism: General symptoms include weight loss, sweating, tremor, muscle wasting, and painless weakness. Occasional patients have myalgia, cramps, and bulbar and ocular muscle weakness. Ocular symptoms (diplopia, reduced blinking, lid droop) and skin disease may be present, especially in the case of Graves disease.
  • Parathyroid dysfunction
    • Hypoparathyroidism: Tetany with or without carpopedal spasm is seen. Muscle pain, cramps, and spasms are present in up to one half of patients. Muscle weakness is usually mild. General symptoms include short stature with rounded face, thickened calvarium and other bony abnormalities, and neurological symptoms (eg, seizures, mentation defects).
    • Hyperparathyroidism: Muscle wasting and myopathy (ie, proximal muscle weakness) are common. Other symptoms may include the findings denoted by the well-known phrase "(painful) bones, (renal) stones, (gastrointestinal) groans, and (psychiatric) moans." Notably, depression, mentation defects, memory loss, and mood changes may be present. Also, renal stones are an almost constant feature of this disease syndrome.
  • Pituitary dysfunction: The myopathy from pituitary disease may be a result of secondary adrenal dysfunction or other endocrine disturbance.
    • Hypopituitarism: Often, the myopathy results from secondary adrenal dysfunction. General symptoms include amenorrhea, loss of libido, alabaster skin, lethargy, constipation, and cold intolerance.
    • Hyperpituitarism: As with hypopituitarism, secondary adrenal effects may be responsible for the myopathy. General symptoms include infertility, impotence, headaches, and mass effects of the pituitary tumor.
  • Polymyalgia rheumatica (PMR) and temporal arteritis (TA): Although research is just beginning, Imrich and colleagues note that age-related changes in the neuroendocrine system could represent a pathogenic factor for PMR and/or TA in genetically disposed.


Physical examination should focus on the entire body, as the endocrine diseases usually present with multiple system findings. An endocrine tumor is in the differential diagnosis, and signs of a hormone-secreting tumor may be seen on examination.

  • Neck flexor weakness reflects proximal muscle weakness and may be noted in myopathies; dysphagia from bulbar weakness also can occur.
  • Respiratory muscle weakness may occur in endocrine disease.[7]
  • Physical examination findings should correlate with the underlying endocrine disease. However, the following patterns may be observed:
    • In thyrotoxicosis, muscle weakness and atrophy may affect muscles of proximal arms more than those of the legs.
    • Muscle stretch reflexes are usually present (may be depressed) even in weak muscles.
  • Adrenal dysfunction
    • Hypoadrenalism: Examination may show an ataxic gait. Cognition may be poor.
    • Hyperadrenalism: Papilledema and other signs and symptoms of increased intracranial pressure may be present.
  • Thyroid dysfunction
    • Hypothyroidism: Motor movements can have a reduced velocity with delayed relaxation of muscle stretch reflexes. Median neuropathy at the wrist commonly accompanies this diagnosis.
    • Hyperthyroidism: In addition to the findings of Graves disease, muscle weakness with atrophy of the pelvic girdle musculature may be present.
  • Parathyroid dysfunction
    • Hypoparathyroidism: Tetany is a common finding; cataracts may be present. Increased intracranial pressure is not a constant finding, but may be present.
    • Hyperparathyroidism: Myopathy is a prominent finding. Both symmetric weakness of the proximal limbs and atrophy are present.
  • Pituitary dysfunction: The myopathy from pituitary disease may be a result of secondary adrenal dysfunction or other endocrine disturbance.
    • Hypopituitarism: Multiple endocrinopathies may result from pituitary dysfunction. Pituitary tumor may have focal mass effects.
    • Hyperpituitarism: Multiple endocrinopathies may result from pituitary dysfunction. Mass lesions may have local effects.

Physicians must be especially alert in the following scenarios:

  • Physicians must be alert to the possibility of an endocrine etiology in cases of pure muscle weakness—even in the absence of systemic findings—as endocrine diseases may be associated with significant morbidity or mortality.
  • Siafakas et al reported evidence of respiratory muscle weakness in endocrine disease.
  • Physicians must be alert to the possibility of an endocrine etiology in cases of new-onset psychosis or behavior disturbance.
  • Physicians must be alert to the possibility of malignancy as the underlying etiology for any endocrinopathy.
Contributor Information and Disclosures

Wayne E Anderson, DO, FAHS, FAAN Assistant Professor of Internal Medicine/Neurology, College of Osteopathic Medicine of the Pacific Western University of Health Sciences; Clinical Faculty in Family Medicine, Touro University College of Osteopathic Medicine; Clinical Instructor, Departments of Neurology and Pain Management, California Pacific Medical Center

Wayne E Anderson, DO, FAHS, FAAN is a member of the following medical societies: California Medical Association, American Headache Society, San Francisco Medical Society, San Francisco Medical Society, International Headache Society, California Neurology Society, San Francisco Neurological Society, American Academy of Neurology, California Medical Association

Disclosure: Received honoraria from Teva for speaking and teaching; Received grant/research funds from Allergan for other; Received honoraria from Insys for speaking and teaching; Received honoraria from DepoMed for speaking and teaching.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Neil A Busis, MD Chief of Neurology and Director of Neurodagnostic Laboratory, UPMC Shadyside; Clinical Professor of Neurology and Director of Community Neurology, Department of Neurology, University of Pittsburgh Physicians

Neil A Busis, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Additional Contributors

Dianna Quan, MD Professor of Neurology, Director of Electromyography Laboratory, University of Colorado School of Medicine

Dianna Quan, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Neurological Association

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Ling Xu, MD to the development and writing of this article.

  1. Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, D'Antona G. Steroid myopathy: some unresolved issues. J Endocrinol Invest. 2011 May. 34(5):370-5. [Medline].

  2. Lin SH, Huang CL. Mechanism of thyrotoxic periodic paralysis. J Am Soc Nephrol. 2012 Jun. 23(6):985-8. [Medline]. [Full Text].

  3. Costa RM, Dumitrascu OM, Gordon LK. Orbital myositis: diagnosis and management. Curr Allergy Asthma Rep. 2009 Jul. 9(4):316-23. [Medline].

  4. Rodolico C, Toscano A, Benvenga S, et al. Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Thyroid. 1998 Nov. 8(11):1033-8. [Medline].

  5. Imrich R, Bosak V, Rovensky J. Polymyalgia rheumatica and temporal arteritis: the endocrine relations and the pathogenesis. Review. Endocr Regul. 2006 Sep. 40(3):83-9. [Medline].

  6. Mathew V, Misgar RA, Ghosh S, Mukhopadhyay P, Roychowdhury P, Pandit K, et al. Myxedema coma: a new look into an old crisis. J Thyroid Res. 2011. 2011:493462. [Medline]. [Full Text].

  7. Siafakas NM, Alexopoulou C, Bouros D. Respiratory muscle function in endocrine diseases. Monaldi Arch Chest Dis. 1999 Apr. 54(2):154-9. [Medline].

  8. Romeo V. Myotonic Dystrophy Type 1 or Steinert's disease. Adv Exp Med Biol. 2012. 724:239-57. [Medline].

  9. Li Cavoli G, Mulè G, Rotolo U. Renal involvement in psychological eating disorders. Nephron Clin Pract. 2011. 119(4):c338-41; discussion c341. [Medline].

  10. Nilsson MI, Nissar AA, Al-Sajee D, Tarnopolsky MA, Parise G, Lach B, et al. Xin is a marker of skeletal muscle damage severity in myopathies. Am J Pathol. 2013 Dec. 183(6):1703-9. [Medline].

  11. al-Lozi MT, Pestronk A, Lee WC, et al. Rapidly evolving myopathy with myosin-deficient muscle fibers. Ann Neurology. 1994 Mar. 35(3):257-9. [Medline].

  12. Aminoff MJ. Electromyography in Clinical Practice. 3rd ed. Churchill Livingstone; 1998.

  13. Benvenga S, Toscano A, Rodolico C, et al. Endocrine evaluation for muscle pain. J R Soc Med. 2001 Aug. 94(8):405-7. [Medline].

  14. Engel AG. Electron microscopic observations in primary hypokalemic and thyrotoxic periodic paralyses. Mayo Clin Proc. 1966 Nov. 41(11):797-808. [Medline].

  15. Engel AG, Fransini-Armstrong C. Endocrine myopathies. In: Myology. Vol 2. McGraw-Hill. 1994:1726-47.

  16. Engel AG, Fransini-Armstrong C, eds. Endocrine myopathies. In: Myology. 2nd ed. McGraw-Hill. 1994.

  17. Fenichel GM. Clinical Pediatric Neurology: A Signs and Symptoms Approach. 2nd ed. WB Saunders Co. 1993.

  18. Ghilardi G, Gonvers JJ, So A. Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection. Br J Rheumatol. 1998 Dec. 37(12):1349-51. [Medline].

  19. Godby A, Bergstresser PR, Chaker B, Pandya AG. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998 Feb. 38(2 Pt 2):289-94. [Medline].

  20. Horak HA, Pourmand R. Endocrine myopathies. Neurol Clin. 2000 Feb. 18(1):203-13. [Medline].

  21. Ikeda H, Yoshimoto T, Ogawa Y, Mizoi K, Murakami O. Clinico-pathological study of Cushing's disease with large pituitary adenoma. Clin Endocrinol (Oxf). 1997 Jun. 46(6):669-79. [Medline].

  22. Mastaglia FL. Endocrine myopathies In: Skeletal Muscle Pathology. Churchill Livingstone. 1992.

  23. Mastaglia FL. Endocrine myopathies. In: Lord Walton of Detchant, ed. Skeletal Muscle Pathology. 2nd ed. Churchill Livingstone. 1992:493-509.

  24. McNab TL, Khandwala HM. Acromegaly as an endocrine form of myopathy: case report and review of literature. Endocr Pract. 2005 Jan-Feb. 11(1):18-22. [Medline].

  25. Ohkoshi N, Ishii A, Shiraiwa N, et al. Dysfunction of the hypothalamic-pituitary system in mitochondrial encephalomyopathies. J Med. 1998. 29(1-2):13-29. [Medline].

  26. Perrot S, Le Jeunne C. [Steroid-induced myopathy]. Presse Med. 2012 Apr. 41(4):422-6. [Medline].

  27. Poirier J, Gray F, Escourolle R. Manual of Basic Neuropathology. WB Saunders Co. 1990.

  28. Pourmand R. Metabolic myopathies. A diagnostic evaluation. Neurol Clin. 2000 Feb. 18(1):1-13. [Medline].

  29. Saguil A. Evaluation of the patient with muscle weakness. Am Fam Physician. 2005 Apr 1. 71(7):1327-36. [Medline].

  30. Schapira AH, Griggs RC. Endocrine myopathies. In: Muscle Disease. Vol 6. Butterworth-Heinemann. 2000:181-92.

  31. Soni M, Amato AA. Myopathic complications of medical disease. Semin Neurol. 2009 Apr. 29(2):163-80. [Medline].

  32. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). J Clin Endocrinol Metab. 2012 Sep. 97(9):2990-3011. [Medline].

  33. Van Linthoudt D, Schumacher HR Jr, Algeo S, et al. Scleromyxedema with myopathy and hyperthyroidism. J Rheumatol. 1996 Jul. 23(7):1299-301. [Medline].

  34. Vantyghem MC, Dobbelaere D, Mention K, Wemeau JL, Saudubray JM, Douillard C. Endocrine manifestations related to inherited metabolic diseases in adults. Orphanet J Rare Dis. 2012 Jan 28. 7:11. [Medline]. [Full Text].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.